Ferozsons in talks to produce Remdesivir.

KARACHI -- Ferozsons Laboratories announced on Monday that its subsidiary BF Biosciences Ltd (BFBL) was in negotiations to enter into a non-exclusive license agreement with Gilead Sciences Inc for the manufacture and sale of Remdesivir to supply Pakistan and 126 other countries.

'There is no obligation at this time for any party to execute any transaction,' Ferozsons told the PSX in a notice.

Ferozsons share hit the upper circuit in trading on Monday as investors fell for the company stocks which also saw several other pharma companies' record substantial gains.

It went on to say in the notice that 'If an agreement is executed by Gilead and BFBL, once production...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT